 That's due to inflation cooling, which has pushed bond yields lower for the past few weeks. Pfizer says it's moving forward with the weight loss pill as an alternative to current injection weight loss drugs that are currently dominating the market. The drug company says the pill will progress to a mid-stage study sometime in the second half of this year. Analysts believe the weight loss drug market could reach $130 billion by the end of the decade, with Pfizer saying they hope to capture a third of that market.